After Reaching Milestone, Is Biodelivery Sciences International Inc (NASDAQ:BDSI)’s Short Interest Revealing Something?

May 17, 2018 - By Larry Park

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Logo

Investors sentiment increased to 2.13 in Q4 2017. Its up 0.46, from 1.67 in 2017Q3. It increased, as 4 investors sold BioDelivery Sciences International, Inc. shares while 11 reduced holdings. 15 funds opened positions while 17 raised stakes. 22.65 million shares or 11.32% more from 20.34 million shares in 2017Q3 were reported.
Millennium Limited Liability Com reported 104,960 shares. Valley National Advisers Incorporated holds 37,715 shares or 0.04% of its portfolio. Moreover, Morgan Stanley has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Barclays Public Ltd Co invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Next Fincl Group Inc accumulated 58,850 shares. Goldman Sachs Grp holds 0% or 75,593 shares in its portfolio. Balyasny Asset Mngmt Limited Company has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Alphamark Advisors accumulated 1,100 shares or 0% of the stock. 462,533 are held by Geode Capital Management Ltd Liability. Salem Investment Counselors accumulated 17,200 shares or 0.01% of the stock. Citadel Advsrs Ltd Co invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Ameriprise, a Minnesota-based fund reported 1.31M shares. Blackrock Inc holds 0% or 1.16M shares in its portfolio. Earnest Prtnrs Ltd Limited Liability Company reported 2,800 shares stake. Gru One Trading L P invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Since January 2, 2018, it had 0 insider buys, and 4 insider sales for $2.52 million activity. On Tuesday, April 3 De Paolantonio Ernest Robert sold $134,013 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) or 64,155 shares. Sirgo Mark A sold $1.94M worth of stock.

The stock of Biodelivery Sciences International Inc (NASDAQ:BDSI) registered an increase of 3.19% in short interest. BDSI’s total short interest was 2.96 million shares in May as published by FINRA. Its up 3.19% from 2.87 million shares, reported previously. With 136,500 shares average volume, it will take short sellers 22 days to cover their BDSI’s short positions. The short interest to Biodelivery Sciences International Inc’s float is 6.76%.

The stock increased 21.79% or $0.42 during the last trading session, reaching $2.38. About 1.51 million shares traded or 324.74% up from the average. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 10.53% since May 17, 2017 and is uptrending. It has underperformed by 1.02% the S&P500.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $140.77 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 26.39 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 3 analysts covering BioDelivery (NASDAQ:BDSI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery had 7 analyst reports since November 27, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Monday, May 7. The firm has “Buy” rating given on Thursday, March 15 by Cantor Fitzgerald. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Monday, November 27. H.C. Wainwright has “Buy” rating and $5.0 target. H.C. Wainwright maintained the shares of BDSI in report on Tuesday, February 6 with “Buy” rating. The firm has “Buy” rating given on Monday, March 19 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Friday, April 13.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Nasdaq.com which released: “BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital” on May 03, 2018, also Streetinsider.com with their article: “BioDelivery Sciences (BDSI) Reports Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business” published on May 17, 2018, Benzinga.com published: “Mid-Afternoon Market Update: Dow Turns Lower; JC Penney Shares Plunge” on May 17, 2018. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Seekingalpha.com and their article: “FDA OKs first non-opioid treatment for opioid withdrawal” published on May 16, 2018 as well as Globenewswire.com‘s news article titled: “BioDelivery Sciences Announces Pricing of $50 Million Equity Financing” with publication date: May 17, 2018.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: